Group 1 - Eli Lilly is gaining market share in a lucrative market, which could act as a catalyst for stock price increase [1]

Company Overview - Eli Lilly and Company is represented by Lucas Montarce, CFO, and Mike Czapar, SVP of Investor Relations, during the BofA Securities 2025 Health Care Conference [1][2]. Industry Context - The discussion includes insights on drug pricing policies, particularly referencing the potential impact of political actions, such as those from former President Trump, on the pharmaceutical industry [3]. Financial Leadership - Lucas Montarce has been with Eli Lilly since 2021 and has held the CFO position since September 2024, indicating a strong leadership presence in both U.S. and international roles [1].

Summary of Eli Lilly (LLY) 2025 Conference Call Company Overview - **Company**: Eli Lilly (LLY) - **Date of Conference**: May 15, 2025 - **Key Speakers**: Lucas Montarce (CFO), Mike Zapar (SVP, Investor Relations) Industry Context - **Industry**: Pharmaceutical and Biotech - **Key Topics**: Drug pricing, manufacturing, obesity treatment, market expansion Core Points and Arguments Drug Pricing and Policy - The recent executive order regarding drug pricing is seen as a potential threat, with the administration aiming to lower drug prices, which may involve concessions from the pharmaceutical industry [3][4][6] - Eli Lilly supports efforts to make healthcare more affordable, including direct patient access programs like Lilly Direct [5][10] - The company believes that the comparison of U.S. drug prices to international prices is not appropriate due to different market structures [5][6] - There is optimism about working with the administration to find common ground on drug pricing [7][10] Manufacturing and Cost Implications - Eli Lilly is investing significantly in expanding its manufacturing capacity, increasing its investment from $23 billion to $50 billion since 2020 [17][18] - The shift of manufacturing back to the U.S. may lead to increased production costs and impact gross margins, but the company is confident in offsetting these costs through efficiencies [16][20][21] - The company is focused on maintaining stable gross margins despite potential headwinds from increased production costs [15][20] Obesity Treatment Market - Eli Lilly's obesity treatment pricing is expected to remain stable in the near term due to a duopoly with limited competition [22][23] - The company anticipates price erosion in the future as more competitors enter the market, but believes it can manage this through disciplined pricing strategies [37][38] - The cash pay channel, Lilly Direct, is seen as a way to provide access to patients without insurance coverage, with a gradual increase in employer opt-in rates [40][46] International Market Opportunities - Eli Lilly has launched its products in 40 countries, with significant potential in markets like China, India, and Mexico, which have large populations of potential patients [50][51][53] - The company estimates that there are approximately 900 million patients globally who could benefit from its obesity and diabetes treatments [50][52] - The penetration rate in these international markets is currently low, indicating substantial growth opportunities [50][52] Future Product Development - Eli Lilly is advancing its oral GLP-1 medication, orfaglipirone, with multiple studies underway, and expects significant market potential both in the U.S. and internationally [56][59] - The preference for oral medications varies by region, with a higher acceptance of injectables in the U.S. compared to other markets [60][61] Additional Important Insights - The company is focused on maintaining a disciplined pricing strategy across its product portfolio, despite external pressures and competition [25][26] - Eli Lilly is actively monitoring the impact of Medicare pricing negotiations on its business, noting that Medicare represents a small portion of its overall revenue [35][36] - The company is optimistic about the growth potential in the obesity treatment market, emphasizing the importance of expanding market access and patient mobilization [30][32] This summary captures the key points discussed during the Eli Lilly conference call, highlighting the company's strategies, market opportunities, and challenges in the pharmaceutical industry.

Group 1: Market Overview - The stock market experienced significant volatility during President Trump's first 100 days in office, with the S&P 500 and Nasdaq Composite dropping by 7% and 11% respectively [1][2] - Various factors, including competing AI platforms from China, geopolitical tensions, and tariffs, have put pressure on capital markets this year [2] Group 2: Tesla - Tesla's stock was heavily influenced by the Trump administration, with a notable 31% decline during the first 100 days due to backlash against CEO Elon Musk's involvement in the Department of Government Efficiency (DOGE) program [4][8] - Musk's divided attention and the negative public perception of his actions led to concerns about Tesla's brand reputation and investor confidence [8] - Following the end of Trump's first 100 days, Tesla's stock rebounded by 9%, aided by a temporary easing of tariffs between the U.S. and China, but uncertainty remains regarding its competitive position in the EV market [9][10] Group 3: Eli Lilly - Eli Lilly's share prices rose by 22% during Trump's first 100 days, although this gain was preceded by significant pressure [11][13] - The potential for tariffs on pharmaceuticals and the executive order for "most-favored-nation pricing" could pose challenges for Eli Lilly in the near term [14][15] - Despite short-term headwinds, Eli Lilly's diversified operations across multiple healthcare sectors and global presence suggest that long-term investors may find buying opportunities during any dips [16]

Core Viewpoint - Eli Lilly and Company has experienced a significant stock decline of 17% in May, attributed to mixed earnings results and competitive pressures in the obesity market, particularly from CVS Caremark's partnership with Novo Nordisk [1][3][30] Financial Performance - Lilly reported mixed earnings on May 1, missing first-quarter earnings estimates but exceeding sales expectations, with key drugs Mounjaro, Zepbound, Jardiance, and Taltz performing well [1][2] - Mounjaro and Zepbound generated combined sales of $6.15 billion in Q1 2025, accounting for approximately 48% of total revenues [6][30] - Despite better-than-expected sales, Lilly's stock fell 11% on the earnings announcement day due to the earnings miss and lowered EPS guidance [2][30] Product Performance - Sales of Mounjaro and Zepbound have shown strong growth, with Mounjaro leading in new prescriptions for type II diabetes and Zepbound holding a 60% market share in the anti-obesity market [8][9] - Lilly's new drugs, including Omvoh, Jaypirca, Ebglyss, and Kisunla, are contributing to top-line growth alongside Mounjaro and Zepbound [12][13] Market Dynamics - The obesity market is projected to reach $100 billion by 2030, with increasing competition from companies like Amgen and Viking Therapeutics developing GLP-1-based therapies [16][18] - CVS Caremark's partnership with Novo Nordisk to promote Wegovy as its preferred GLP-1 therapy has raised concerns about market share for Lilly's Zepbound [3][28] Future Outlook - Lilly maintains its sales guidance for 2025, expecting revenues between $58.0 billion and $61.0 billion, reflecting a 32% year-over-year growth driven by Mounjaro and Zepbound [30] - The company is investing in expanding its pipeline, with several new drugs in development and plans for regulatory filings for orforglipron by the end of 2025 [14][15] Stock Valuation - Lilly's stock has underperformed the industry, declining 3.2% year-to-date compared to the industry's 2.4% decrease [19] - Estimates for Lilly's 2025 earnings have decreased from $23.49 to $22.20 per share over the past month, indicating a downward trend in earnings expectations [24][30]

Core Insights - Eli Lilly's Zepbound (tirzepatide) demonstrated superior efficacy in weight loss compared to Wegovy (semaglutide) in the SURMOUNT-5 trial, achieving an average weight loss of 20.2% versus 13.7% at 72 weeks [1][2][3] Group 1: Trial Results - Zepbound participants lost an average of 50.3 lbs (22.8 kg), while Wegovy participants lost an average of 33.1 lbs (15.0 kg), indicating a 47% greater relative weight loss with Zepbound [2] - In key secondary endpoints, 64.6% of Zepbound participants achieved at least 15% weight loss compared to 40.1% for Wegovy [2][5] - Zepbound also showed a greater average waist circumference reduction of 7.2 inches (18.4 cm) compared to 5.1 inches (13.0 cm) for Wegovy [2][5] Group 2: Safety and Tolerability - The safety profile of Zepbound was consistent with previous trials, with gastrointestinal-related adverse events being the most common and generally mild to moderate [5] - 6.1% of Zepbound participants discontinued treatment due to adverse events, compared to 8.0% for Wegovy [5] Group 3: Product Information - Tirzepatide is marketed as Zepbound in the U.S. for adults with obesity or overweight with weight-related medical problems, and as Mounjaro for type 2 diabetes [6][10] - Zepbound is FDA-approved for adults with moderate-to-severe obstructive sleep apnea and obesity [10]

Core Insights - President Trump's second term has posed challenges for investors, particularly due to the imposition of tariffs on imports, which may soon extend to the pharmaceutical industry, affecting companies like Eli Lilly [1][2][4] - Eli Lilly has been proactive in addressing potential tariff impacts by investing significantly in domestic manufacturing, with a recent announcement of a $27 billion investment, totaling about $50 billion since 2020 [6][7] Industry Overview - The pharmaceutical industry has largely avoided tariffs so far, but this may change as the administration plans to introduce pharmaceutical-specific tariffs [2][4] - Eli Lilly's CEO has indicated that the current reprieve from tariffs is unlikely to last, suggesting that the industry should prepare for increased manufacturing costs and potential impacts on innovation [4][5] Company Performance - Eli Lilly reported a remarkable 45% year-over-year revenue increase in the first quarter, reaching $12.7 billion, showcasing strong financial performance compared to peers [9] - Despite a decline in share price following earnings release due to conservative fiscal year 2025 guidance, this was attributed to acquisition-related expenses rather than ongoing operational issues [10] Strategic Positioning - Eli Lilly is enhancing its local manufacturing capabilities to mitigate tariff impacts, with plans to complete 10 active manufacturing projects that will allow for domestic production of therapies [6][7] - The company maintains a strong position in the weight management market, with Zepbound's sales rising to $2.3 billion from $517.4 million year-over-year, indicating robust product performance [10] Future Outlook - Eli Lilly's pipeline in the GLP-1 space is highly regarded, with expectations for continued strong top-line growth as new products gain approval [11] - The company's ability to adapt to changing economic conditions and its proven innovative capabilities position it favorably for future success, making it an attractive investment despite tariff uncertainties [8][11]

Core Viewpoint - Companies like Eli Lilly and Visa are positioned to potentially reach a market cap of $1 trillion by 2030, making them attractive long-term investment opportunities due to their growth prospects and market positions [1]. Eli Lilly - Eli Lilly has a current market cap of just under $737 billion and needs a compound annual growth rate (CAGR) of 6.3% to reach $1 trillion by 2030, which is below the market's historical performance [3][4]. - The company faces challenges such as market-wide issues and high valuation metrics, with a forward price-to-earnings (P/E) ratio of 35.4, significantly higher than the healthcare sector average of 16 [3][4]. - Eli Lilly's innovative pipeline includes investigational weight management medicines and a promising gene therapy for deafness, positioning it well in the growing weight loss market [5][7]. - The company has a strong dividend growth history, which can enhance returns for long-term investors [7]. Visa - Visa's market cap is just under $679 billion, requiring a CAGR of 8.1% to achieve a $1 trillion valuation by 2030, which is manageable within equity market standards [8]. - The company benefits from inflation as its fees are transaction-based, potentially increasing revenue during economic fluctuations [8][9]. - Visa has demonstrated resilience during economic downturns, maintaining strong performance despite challenges like the pandemic [9][10]. - The company enjoys a dominant position in the payment technology sector with a strong network effect, making it difficult for competitors to disrupt its market [10]. - Visa has significant growth prospects due to the ongoing shift from cash to credit and debit transactions, as well as the expansion of e-commerce [11].

Core Viewpoint - A federal judge has ruled that the FDA's determination regarding the shortage of Eli Lilly's drug tirzepatide has ended, and the pharmaceutical company is prohibited from continuing to produce generic versions of the weight loss medication [1] Summary by Relevant Sections - **FDA's Decision**: The FDA legally removed tirzepatide from the shortage list last year, which the court has upheld [1] - **Court Ruling**: Judge Mark T. Pittman of the Northern District of Texas approved the FDA's motion for summary judgment, affirming the agency's position [1] - **Court Records**: The opinion from the court is currently sealed but will eventually be unsealed [1]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $203 million, reflecting a 3% increase year-over-year [25] - Prescription transaction revenue and manufacturer solutions revenue increased by 217% year-over-year [25] - Adjusted EBITDA for Q1 2025 was $69.8 million, an 11% increase year-over-year, with an adjusted EBITDA margin of 34.4% [25] Business Line Data and Key Metrics Changes - The prescription marketplace and manufacturer solutions offerings saw significant growth, with a focus on enhancing partnerships with pharmacies and pharmaceutical manufacturers [10][18] - The integrated savings program (ISP) is being evaluated for expansion into non-covered medications, indicating a strategic shift to enhance value [17] Market Data and Key Metrics Changes - Over 12 million consumers and 750,000 healthcare professionals (HCPs) utilized GoodRx in Q1 2025, demonstrating strong platform engagement [9] - The company noted ongoing uncertainty in the macroeconomic environment, including regulatory changes and consumer sentiment shifts, which could impact business [11] Company Strategy and Development Direction - The company is focused on high-impact initiatives to strengthen its position in the pharmacy ecosystem, including leadership changes and strategic partnerships [5][6] - GoodRx aims to enhance its e-commerce capabilities and integrate more deeply with pharmacy operations to improve consumer experience and pharmacy profitability [16][21] - The company is committed to investing in its brand and expanding its value proposition to consumers and HCPs [13][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the Rite Aid bankruptcy and emphasized the importance of maintaining relationships with pharmacy partners to ensure smooth transitions for consumers [11][12] - The company remains optimistic about its future growth opportunities, particularly in expanding its partnerships and enhancing its service offerings [20][22] Other Important Information - The company ended Q1 2025 with $301 million in cash and $91.7 million of unused capacity on its revolving line of credit, indicating strong liquidity [25] - A share repurchase program is in place, with approximately $189 million remaining under the $450 million authorization [25] Q&A Session Summary Question: What are the most important high-impact initiatives for the company? - Management highlighted closer partnerships with retail pharmacies and expanding brand partnerships as key initiatives to drive growth [36] Question: How has the company historically managed store closures and consumer retention? - Management indicated that they are actively working to ensure smooth transitions for consumers during pharmacy closures, emphasizing the strength of the GoodRx brand [42][45] Question: What is the impact of the shift to cost-plus pricing by larger PBMs on the company's legacy model? - Management stated that a significant portion of their business already operates on cost-plus pricing, and they remain indifferent to the reimbursement mechanism [54] Question: Is there still an opportunity with GLP medications? - Management confirmed that opportunities with GLP medications continue to exist, and they are in discussions with manufacturers to enhance consumer access [58] Question: How does the company view its exposure to Medicare beneficiaries? - Management noted that less than 30% of users are Medicare eligible, and the impact of changes in Medicare out-of-pocket costs is minimal [93][95] Question: What is the company's strategy regarding biosimilars? - Management expressed optimism about the uptake of biosimilars and their alignment with the company's affordability narrative [97]